My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

2.600 UNCHANGED

Streaming Delayed Price Updated: 4:15 PM EST, Feb 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

3 Monster Biotech Stocks to Buy Before 2025 ↗

September 02, 2024

These companies are nearly in the sweet spot of risk versus reward in biotech.

Via The Motley Fool

Up 47% in 2024: Where Will Iovance Biotherapeutics Be in 5 Years? ↗

August 27, 2024

This company's new cancer therapy is producing remarkable results, but the company is losing money at a frightening pace.

Via The Motley Fool

Looking Into Iovance Biotherapeutics's Recent Short Interest ↗

August 16, 2024

Via Benzinga

This 1 Big Risk Is Also 1 Big Opportunity for Iovance Biotherapeutics Stock ↗

August 14, 2024

It could demonstrate a few capabilities that no other biotech has as of yet.

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 12, 2024

Via Benzinga

Iovance Biotherapeutics Stock: A Deep Dive Into Analyst Perspectives (7 Ratings) ↗

August 12, 2024

Via Benzinga

What the Options Market Tells Us About Iovance Biotherapeutics ↗

August 08, 2024

Via Benzinga

How Is The Market Feeling About Iovance Biotherapeutics? ↗

July 22, 2024

Via Benzinga

Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday ↗

August 09, 2024

Via Benzinga

Why Iovance Biotherapeutics Shares Are Soaring Today ↗

August 09, 2024

The biopharma company is proving its recently approved cancer therapy is marketable.

Via The Motley Fool

Why Is Iovance Bio (IOVA) Stock Up 18% Today? ↗

August 09, 2024

Iovance Biotherapeutics stock is gaining as IOVA investors react to strong Q2 earnings beats and positive guidance for 2024 and 2025.

Via InvestorPlace

Topics Earnings

Skin Cancer-Focused Iovance Biotherapeutics Reports Better-Than-Expected 2024, 2025 Outlook, Stock Surges ↗

August 09, 2024

Iovance Biotherapeutics stock up 23.2% after issuing upbeat guidance for 2024 and 2025, beating Q2 earnings expectations.

Via Benzinga

Why Doximity Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket ↗

August 09, 2024

Via Benzinga

IOVA Stock Earnings: Iovance Biotherapeutics Beats EPS, Beats Revenue for Q2 2024 ↗

August 08, 2024

IOVA stock results show that Iovance Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

10 Best Small and Mid-Cap Stocks to Consider Buying in August ↗

August 01, 2024

A shift in market dynamics could favor these 10 growth stocks.

Via The Motley Fool

Iovance Biotherapeutics Attracted a Downgrade. Is It Time to Sell? ↗

July 31, 2024

Find out how concerned investors should be about setbacks for this company's revolutionary new cancer therapies.

Via The Motley Fool

Why Iovance Biotherapeutics Stock Stumbled Today ↗

July 29, 2024

One pundit warns of apparent manufacturing issues with the company's melanoma drug.

Via The Motley Fool

Iovance Biotherapeutics Price Forecast Slashed By 40% On Mutated Uptake For Its Newly Approved Skin Cancer Cell Therapy ↗

July 29, 2024

Piper Sandler downgraded Iovance Biotherapeutics due to a slow launch of Amtagvi (lifileucel), a skin cancer treatment. Despite patient demand, extended treatment timelines and low infusion rates led...

Via Benzinga

Life May Soon Get Easier for (Some) Biotech Stocks. Here's Why. ↗

July 29, 2024

The Federal Reserve's fight against inflation may soon yield financial benefits.

Via The Motley Fool

Topics Economy

Abbott, Integra LifeSciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

July 29, 2024

Via Benzinga

ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio? ↗

July 28, 2024

Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72%

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

July 23, 2024

Via Benzinga

7 ‘Death Cross’ Stocks That Could Be Contrarian Buys ↗

July 17, 2024

Although death cross stocks sound incredibly ominous, they could be the ideal time to consider a contrarian position.

Via InvestorPlace

Is Iovance Biotherapeutics a Millionaire Maker? ↗

July 14, 2024

This biotech's future is bright, but how good could it get for investors?

Via The Motley Fool

3 Under-$10 Biotech Stocks That Could Make You Rich ↗

July 11, 2024

Discover three under-$10 biotech stocks with potential to make you rich with huge returns on investment through an in-depth analysis.

Via InvestorPlace

Methode Electronics Posts Strong Sales, Joins QuantumScape, Ribbon Communications And Other Big Stocks Moving Higher On Thursday ↗

July 11, 2024

Via Benzinga

Is It Too Late to Buy Iovance Biotherapeutics Stock? ↗

June 28, 2024

The stock is down more than 50% from its 52-week high.

Via The Motley Fool

3 Top Penny Stocks to Skyrocket Your Wealth in 2024 ↗

June 21, 2024

Find out about the top penny stocks to buy this year for a chance to see incredible results down the road as they soar to new heights.

Via InvestorPlace

The Case for Buying Iovance Biotherapeutics Stock Just Got Even Better. Here's Why ↗

June 10, 2024

New data indicate that its cell therapy could soon find a larger market.

Via The Motley Fool

Oncotelic Therapeutics (OTC: OTLC) Inks Deal With Mosaic ImmunoEngineering To Sell Clinical-Stage Necroptosis Cancer Therapy Assets

May 29, 2024

Oncotelic Therapeutics (OTC: OTLC) Inks Deal With Mosaic ImmunoEngineering To Sell Clinical-Stage Necroptosis Cancer Therapy Assets

Via News Direct

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.